On November 12, 2024, Altimmune, Inc., a clinical-stage biopharmaceutical company, reported its financial results for the third quarter ending September 30, 2024, and provided updates on its business operations. The company announced the completion of enrollment in the Phase 2b IMPACT trial of pemvidutide for metabolic dysfunction-associated steatohepatitis (MASH), with top-line efficacy data expected in Q2 2025. Altimmune also completed an End-of-Phase 2 meeting with the FDA regarding its obesity program and plans to submit Investigational New Drug (IND) applications for pemvidutide in up to three additional indications starting Q4 2024. The company's cash, cash equivalents, and short-term investments totaled $139.4 million as of September 30, 2024. Research and development expenses increased to $19.8 million for the quarter, compared to $18.4 million in the same period the previous...Show More

On November 12, 2024, Altimmune, Inc., a clinical-stage biopharmaceutical company, reported its financial results for the third quarter ending September 30, 2024, and provided updates on its business operations. The company announced the completion of enrollment in the Phase 2b IMPACT trial of pemvidutide for metabolic dysfunction-associated steatohepatitis (MASH), with top-line efficacy data expected in Q2 2025. Altimmune also completed an End-of-Phase 2 meeting with the FDA regarding its obesity program and plans to submit Investigational New Drug (IND) applications for pemvidutide in up to three additional indications starting Q4 2024. The company's cash, cash equivalents, and short-term investments totaled $139.4 million as of September 30, 2024. Research and development expenses increased to $19.8 million for the quarter, compared to $18.4 million in the same period the previous year, primarily due to development activities for pemvidutide. General and administrative expenses rose to $5.0 million from $4.5 million in the same quarter of the previous year. The net loss for the quarter was $22.8 million, or $0.32 per share, compared to a net loss of $20.7 million, or $0.39 per share, in the same period in 2023. Altimmune also highlighted the appointment of Greg Weaver as Chief Financial Officer on November 11, 2024.